



# Surgical Roles in the Management of Metachronous Para-aortic Lymph Node Recurrence and Synchronous Para-aortic Lymph Node Metastasis in Colorectal Cancer Patients

Osama Abd-Elaziz<sup>1</sup> Ramadan M. Ali<sup>1</sup> Mohamed Farouk Amin<sup>1</sup> Ahmed M. Fahmy<sup>2</sup>  
Shereen Elshorbagy<sup>3</sup> Doaa Mandour<sup>4</sup> Rehab Hemedda<sup>4</sup> Ola A. Harb<sup>5</sup> Amr Samir<sup>6</sup>  
Elsayed I. El-Hendawy<sup>1</sup>

<sup>1</sup> Department of General Surgery, Faculty of Medicine, Zagazig University, Zagazig, Egypt

<sup>2</sup> Department of Anesthesia and Intensive Care, Faculty of Medicine, Zagazig University, Zagazig, Egypt

<sup>3</sup> Department of Medical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

<sup>4</sup> Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt

<sup>5</sup> Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

<sup>6</sup> Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Address for correspondence Ola A. Harb, MD, PhD, Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt, 44519 (e-mail: olaharb2015@gmail.com).

J Coloproctol 2022;42(2):131–139.

## Abstract

**Background** The relative rarity of synchronous para-aortic lymph node (PALN) metastasis (SPM) and metachronous PALN recurrence (MPR) in colorectal carcinoma (CRC) patients leads to a limited number of studies on patient management, and no treatment guidelines have been established to date.

**Objective** To assess the prognostic, predictive roles, and long-term outcomes of different management strategies for isolated MPR and SPM in CRC patients to establish the best one.

**Materials and Methods** We included 35 CRC patients with isolated MPR and 25 patients with isolated SPM who underwent curative R0 resection. We performed PALN dissection (PALND) in 15 cases in MPR group and in 10 cases in the SPM group; all remaining patients in both groups underwent chemoradiotherapy (CRT) without further surgical intervention. During the study period of about 5 years, we compared the patients who underwent PALND and those who underwent CRT.

**Results** The overall survival and recurrence-free survival rates were significantly longer in patients who underwent PALND ( $p = 0.049$  and  $0.036$  respectively).

## Keywords

- ▶ colorectal cancer
- ▶ metachronous para-aortic lymph node recurrence
- ▶ synchronous para-aortic lymph node metastasis
- ▶ surgery

received  
July 24, 2021  
accepted after revision  
October 25, 2021  
published online  
January 31, 2022

DOI <https://doi.org/10.1055/s-0042-1742310>.  
ISSN 2237-9363.

© 2022. Sociedade Brasileira de Coloproctologia. All rights reserved.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

**Conclusions** We showed that PALND in cases of CRC patients with SPM and MPR previously submitted to R0 resection was associated with favorable outcomes and better patient survival.

## Introduction

Approximately 2% of colorectal carcinoma (CRC) patients experience isolated metachronous para-aortic lymph node (PALN) recurrence (MPR) after curative surgical excision of the primary tumor.<sup>1</sup> Synchronous PALN metastasis (SPM) is considered a stage-IV disease.<sup>2,3</sup>

Previous studies<sup>4</sup> have established the roles of surgical resection and chemotherapy (CTx) in the management of isolated liver and lung cancer recurrences, which led to improvements in patient prognosis.

The relative rarity of MPR and SPM leads to limited number of studies on patient management, and no treatment guidelines have been established to date.<sup>5</sup>

Curative resection was found to be beneficial for CRC patients with isolated MPR.<sup>5</sup> One study<sup>6</sup> reported that the outcomes of CRC patients after chemoradiotherapy (CRT) were similar to those of the patients who underwent surgical resection.

Moreover, MPR resection below the renal veins can be safely performed and improve prognosis in comparison to non-surgical resection.<sup>7</sup>

Recent studies<sup>9,10</sup> have updated the prognostic predictive parameters for the successful surgical management of SPM, including R0 resection, histological type, number of PALNs, presence of metastatic lateral pelvic lymph node, distant metastases, and preoperative levels of carcinoembryonic antigen (CEA).

No clear predictive parameters for the successful surgical management of MPR have been established to date.

Additionally, no previous studies have assessed the prognostic parameters and role of surgical resection in cases of SPM and MPR in CRC patients.

In the present study, we aimed to assess the prognostic, predictive roles, and long-term outcomes of different management strategies for SPM and MPR in CRC patients—PALN dissection (PALND) and CRT—to establish the best management strategy.

## Materials and Methods

The present prospective cohort study included 60 consecutive CRC patients: 35 patients clinically or radiologically diagnosed with isolated MPR, and 25 patients clinically or radiologically diagnosed with isolated SPM who underwent curative R0 resection (no gross or microscopic residual tumor after surgical excision) from January 2014 to December 2019 at the General Surgery Department, Faculty of Medicine, Zagazig University Hospitals, Zagazig, Egypt. The PALNs are the lymph nodes around the abdominal aorta and inferior vena cava, and recurrence in them

and extending laterally to the psoas major muscles, cranially to the diaphragm, and caudally to the common iliac vessels was confirmed by computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) findings, as well as by the high serum levels of CEA.

We performed PALND in 10 (40%) patients with SPM and in 15 (42.9%) patients with MPR. All remaining patients in both groups underwent CRT without further surgical intervention. During the follow-up (median: 37 months; range: 10 to 55 months), we compared the patients who underwent surgery and those who underwent CRT.

## Exclusion Criteria

Patients with incompletely resected tumors who could not undergo R0 resection, patients with multiple PALNs on both sides of the aorta, and patients with multiple recurrences invading the celiac or superior mesenteric artery were excluded.

After the application of the inclusion and exclusion criteria, 25 patients with SPM and 35 patients with MPR after curative R0 resection were included in the present study.

We collected and reviewed the medical charts, and identified the clinical findings, the pathological characteristics of the tumor, and the survival outcomes of the patients. The perioperative characteristics of patients with PALN recurrence and their management were reported.

The study protocol was approved by the Institutional Review Board (IRB) of the Faculty of Medicine at Zagazig University (IRB No. 2015-1458), and written informed consent was obtained from the patients.

The resectability of the PALNs was evaluated by a multidisciplinary team which included colorectal surgeons, radiologists, pathologists, and oncologists. We divided the location of the recurrent nodes into three classes; left or right sides of the aorta, above the renal vessels, and below the renal vessels.

## Treatment of Patients with MPR

The management of MPR included surgical resection with curative intent, which included wide excision of the involved lymph node in addition to any invaded adjacent tissue, and part of the surrounding normal tissue, to reach free safety resection margins. After surgical resection, patients with histopathological confirmation of MPR underwent adjuvant CTx and CRT. A standard total radiation dose of 48 Gy to 55.4 Gy in fractions of 25 Gy to 31 Gy was applied.

Patients with histopathological confirmation of absence of MPR received no further treatment.

### Treatment of Patients with SPM

Patients with SPM were submitted to surgical resection of the CRC in addition to PALND according to the following parameters: clinical and radiological evidence of metastatic PALN located below the renal vein; with expected negative R0 resection. We performed metastasectomy for most patients after resection of the primary tumor and second stage metastasectomy, as metachronous hepatectomy in some patients.

The PALND procedure included dissection of lymphatic and connective tissues around the abdominal aorta and inferior vena cava between the left renal vein and iliac artery bifurcation.

### Follow-up

After surgical dissection, we followed up all patients every three months to assess tumor markers, and they were submitted to chest and abdominal CTs every six months. All patients with rectal cancer underwent a yearly colonoscopy, and those with colon cancer underwent it every other year, to detect early local recurrence.

We defined local recurrence as recurrence inside the pelvic cavity in cases of rectal cancer, and as recurrence around the tumor area in cases of colon cancer.

### Statistical Analysis

The statistical analysis of the collected data was performed using the Statistical Package for the Social Sciences (IBM SPSS Statistics for Windows, IBM Corp., Armonk, NY, US) software, version 24.0. The Chi-squared test ( $\chi^2$ ) and the Fisher exact were used to calculate the differences among the qualitative variables, and the Mann Whitney test, to calculate the difference among the quantitative variables. Values of  $p < 0.05$  indicate statistically significant differences, and values  $< 0.001$  indicate highly-significant differences. The Kaplan and Meier method was used to detect the overall survival (OS) and the recurrence-free survival (RFS) rates, and the log-rank test was used to compare the survival curves. The time from the date of the diagnosis until the date of death or of the last follow-up is the OS, and the RFS is time from the date of complete response (CR) to the therapy until the date of relapse.

We used the Cox proportional hazards model for the univariate analysis, and statistically significant variables were included in it.

## Results

### Clinicopathological and demographic characteristics of all CRC patients (► Tables 1 and 2)

We included 60 CRC patients, 40 men (66.7%) and 20 woman (33.3%), with a median age of 50 years (range: 30 to 68 years). Conventional adenocarcinoma of the colon was diagnosed in 50 patients (83.3%), right hemicolectomy was performed 50% of the patients, left hemicolectomy, in 26.7%, anterior resection, in 8.3%, and abdominoperineal resection, in 15% of the patients. The median size of the largest PALNs was 15 mm (range: 12 to 20 mm). A total of 50% of the patients underwent preoperative CRT, and 80% were submitted to postoperative

CRT. Complete response to therapy was observed in 65% of the patients, and the OS rate was of 50% (► Figure 1 A,B).

Regarding the demographic, clinical, and pathological parameters, we found no statistically significant differences between patients diagnosed with SPM or MPR, or between patients who underwent PALND and those who did not.

Patients with MPR had better RFS rates than those with SPM (23.6% versus 12.1% respectively;  $p = 0.014$ ), while patients with SPM had better OS rates than those with MPR (60% versus 12.5% respectively;  $p = 0.022$ ) (► Tables 3 and 4; ► Figures 1 C,D).

### Characteristics of PALN Recurrence and PALND in Patients with Metachronous PALN Metastases

A total of 15 MPR patients (42.9%) underwent PALND. After the pathological examination 20% of these patients were diagnosed with chronic granulomatous inflammation and fibrosis; they did not undergo any further treatment, and were followed up.

Following resection, the median size of the largest PALNs was 15 mm (range: 12 to 20 mm). Of the 20 patients (57.1%) treated with CTx alone, 10 were treated with folinic acid, fluorouracil, and irinotecan (FOLFIRI), 2, with folinic acid, fluorouracil, and oxaliplatin (FOLFOX), 4, with capecitabine and oxaliplatin (XELOX), 1, with folinic acid and fluorouracil (LF), 2, with oral capecitabine, and 2%, with targeted agents alone (pembrolizumab and avastin).

We found no significant differences in terms of demographic and clinical characteristics between MPR patients who did and did not undergo PALND.

### Survival Outcomes and Factors Related to the Prognosis of MPR Patients Submitted to PALND

The 15 MPR patients who underwent PALND, had significantly better OS and RFS rates. The multivariate analysis showed that the factors associated with favorable survival were primary tumor in a less advanced stage, performance of CTx, and PALND.

### Characteristics of PALND in SPM Patients

A total of 10 SPM patients (40%) underwent PALND. After the pathological examination, 1 of these patients was diagnosed with lymphadenitis, but underwent no further treatment, and was followed up.

Following resection, the median size of the largest PALNs was 15 mm (range: 12 to 20 mm). Of the 15 patients (60%) treated with CTx alone, 8 were treated with FOLFIRI, 2, with FOLFOX, 2, with XELOX, 1, with LF, 2, with oral capecitabine, and 1, with targeted agents alone (pembrolizumab and avastin).

We found no significant differences in terms of demographic and clinical characteristics between SPM patients who did and did not undergo PALND.

### Survival Outcomes and Factors Related to the Prognosis of SPM Patients Submitted to of PALND

The 10 SPM patients who under went PALND had significantly better OS and RFS rates. The multivariate analysis showed that the factors associated with favorable survival

**Table 1** Clinicopathological features and outcomes of all patients, and of those with SPM and MPR

Variable		SPM		MPR		Total N = 60		p-value
		N = 25		N = 35				
		n	%	n	%	n	%	
Mean age in years (range)		50 (30–65)		50 (32–68)		50 (30–68)		0.976
Histopathological subtype	Conventional adenocarcinoma	22	88.0	28	80.0	50	83.3	0.412
	Mucoid carcinoma	3	12.0	7	20.0	10	16.7	
Site of the primary tumor	Ascending colon	7	28.0	20	57.1	27	45.0	0.038
	Rectosigmoid	10	40.0	4	11.4	14	23.3	
	Descending colon	3	12.0	6	17.1	9	15.0	
	Transverse colon	5	20.0	5	14.3	10	16.7	
Duke stage	A	2	8.0	9	25.7	11	18.3	< 0.001
	B	11	44.0	0	0.0	11	18.3	
	C	12	48.0	13	37.1	25	41.7	
	D	0	0.0	13	37.1	13	21.7	
Type of primary operation	Right hemicolectomy	10	40.0	20	57.1	30	50.0	0.075
	Left hemicolectomy	5	20.0	11	31.4	16	26.7	
	Anterior resection	4	16.0	1	2.9	5	8.3	
	Abdominoperineal resection	6	24.0	3	8.6	9	15.0	
Mean size of largest PALN in millimeters (range)		15 (12–20)		15 (12–20)		15 (12–20)		0.655
PALND	No	15	60.0	20	57.1	35	58.3	0.825
	Yes	10	40.0	15	42.9	25	41.7	
Preoperative chemoradiotherapy	No	13	52.0	17	48.6	30	50.0	0.793
	Yes	12	48.0	18	51.4	30	50.0	
Postoperative chemoradiotherapy	No	5	20.0	7	20.0	12	20.0	> 0.999
	Yes	20	80.0	28	80.0	48	80.0	
	Yes –distant metastasis	1	14.3	6	46.2	7	35.0	

Abbreviations: MPR, metachronous para-aortic lymph node recurrence; PALN, para-aortic lymph node; PALND, para-aortic lymph node dissection; SPM, synchronous para-aortic lymph node metastasis.

were primary tumor in a less advanced stage, performance of CTx, and PALND.

The univariate Cox regression analyses showed that SPM and PALNs with the largest sizes were the most significant predictors of RFS ( $p = 0.04$ ), and, in the multivariate analysis, the most significant predictor of RFS was preoperative CRT ( $p < 0.001$ ) (► **Table 5**).

The univariate Cox regression analyses showed that SPM and the stage in the Duke classification were the most significant predictors of OS ( $p = 0.029$  and  $0.031$  respectively), and in the multivariate analysis, the most significant predictors of OS was preoperative CRT ( $p = 0.003$ ) (► **Table 6**).

## Discussion

In the current study, we showed that the prognosis and the survival rates of CRC patients with SPM or MPR who underwent PALND was better than that of patients who did not undergo surgical excision. Our findings are in line with those of previous studies.<sup>1,8,9</sup> Our study was similar to the one by

Ushigome et al.,<sup>9</sup> which was also restricted to patients who underwent R0 resection of the primary tumor.

We showed that the 5-year OS and RFS rates of the SPM patients who underwent PALND were better than those of patients with general stage-IV tumors; thus, PALND was found to improve patient prognosis. This finding is similar to those of previous reports.<sup>7,10–12</sup>

Ushigome et al.<sup>9</sup> showed that PALND is associated with favorable survival, but it was also associated with early unresectable recurrences. This might be due to the fact that the CRC patients who developed unresectable recurrences and died within one year after PALND were primarily found to have no indication for the procedure. Thus, accurate diagnosis of patients with CRC who should undergo PALND is essential to improve prognosis.

All of these results collectively provide further evidence for the effectiveness of surgical management.

Surgical resection for isolated MPR or SPM has many advantages, as it enables an accurate histopathological confirmation of recurrence or metastasis, particularly in cases

**Table 2** Clinicopathological features and outcomes of patients who did and did not undergo PALND

Variable		PALND				Total N = 60		p-value
		Yes N = 35		No N = 25				
		n	%	n	%	n	%	
Mean age in years (range)		50 (30–68)		54 (32–67)		50 (30–68)		0.192
Gender	Female	12	34.3	8	32.0	20	33.3	0.853
	Male	23	65.7	17	68.0	40	66.7	
Histopathological subtype	Conventional adeno carcinoma	29	82.9	21	84.0	50	83.3	0.907
	Mucoid carcinoma	6	17.1	4	16.0	10	16.7	
Site of the primary tumor	Ascending colon	14	40.0	13	52.0	27	45.0	0.237
	Rectosigmoid	10	28.6	4	16.0	14	23.3	
	Descending colon	7	20.0	2	8.0	9	15.0	
	Transverse colon	4	11.4	6	24.0	10	16.7	
Duke stage	A	6	17.1	5	20.0	11	18.3	0.001
	B	11	31.4	0	0.0	11	18.3	
	C	8	22.9	17	68.0	25	41.7	
	D	10	28.6	3	12.0	13	21.7	
PALN	Synchronous metastasis	15	42.9	10	40.0	25	41.7	0.825
	Meta-chronous recurrence	20	57.1	15	60.0	35	58.3	
Type of primary operation	Right hemicolectomy	14	40.0	16	64.0	30	50.0	0.306
	Left hemicolectomy	11	31.4	5	20.0	16	26.7	
	Anterior resection	4	11.4	1	4.0	5	8.3	
	Abdominoperineal resection	6	17.1	3	12.0	9	15.0	
Mean size of largest PALN in millimeters (range)		14 (12–15)		18 (17–20)		15 (12–20)		< 0.001
Response to treatment	PD	4	11.4	2	8.0	6	10.0	0.962
	SD	4	11.4	3	12.0	7	11.7	
	PR	5	14.3	3	12.0	8	13.3	
	CR	22	62.9	17	68.0	39	65.0	
Preoperative chemoradiotherapy	No	16	45.7	14	56.0	30	50.0	0.432
	Yes	19	54.3	11	44.0	30	50.0	
Postoperative chemoradiotherapy	No	6	17.1	6	24.0	12	20.0	0.513
	Yes	29	82.9	19	76.0	48	80.0	
PALN	Synchronous metastasis	15	42.9	10	40.0	25	41.7	0.825
	Metachronous recurrence	20	57.1	15	60.0	35	58.3	


**Abbreviations:** CR, complete response; PD, progressive disease; PALN, para-aortic lymph node; PALND, para-aortic lymph node dissection; PR, partial response; SD, stable disease.

which might difficult to diagnose by imaging alone. Thus, it also enables the provision of a better therapy, avoids unneeded treatment strategies, and leads to an improvement in patient outcomes and survival,<sup>12</sup> as shown in the present study. These results were similar to those of the study by Kim et al.,<sup>1</sup> in which three patients who underwent PALND were histopathologically confirmed to be negative for malignant recurrence. These patients avoided additional unnecessary adjuvant therapy, and only underwent regular follow-up to detect possible recurrences later on.

Moreover, 20% of the patients with misdiagnosis of recurrence who did not undergo surgical resection may unnecessarily undergo chemotherapy.

The rate of misdiagnosis of recurrence was of about 20%, which was similar to the rates found in previous studies.<sup>13–16</sup>

Regarding the response to therapy in the present study, it was better among the patients who underwent PALND than among those who did not. Moreover, disease progression and further development of distant metastases to the liver, lung,



**Fig. 1** (A) Kaplan-Meier survival curves illustrating the RFS time differences in all the studied CRC patients. (B) Kaplan-Meier survival curves illustrating the OS time differences in all the studied CRC patients (C) Kaplan-Meier survival curves illustrating RSF time differences in patients submitted to PALND. (D) Kaplan-Meier survival curves illustrating OS time differences in patients submitted to PALND.

**Table 3** Recurrence and survival of patients who did and did not undergo para-aortic lymph node dissection (PALND)

Variable		PALND				Total		p-value
		No N = 35		Yes N = 25		n	%	
		n	%	n	%			
Recurrence pattern after PALND	Local	8	34.8%	5	50.0%	13	39.4%	0.411
	Distant	15	65.2%	5	50.0%	20	60.6%	
Death	No	14	40.0%	16	64.0%	30	50.0%	0.047
	Yes	21	60.0%	9	36.0%	30	50.0%	
Relapse*	No	12	44.4%	15	75.0%	27	57.4%	<b>0.036</b>
	Yes	15	55.6%	5	25.0%	20	42.6%	

Note: \* Calculated from patients with documented response to therapy.

**Table 4** Survival rates of patients who did and did not undergo para-aortic lymph nodes dissection (PALND)

PALND	Total	Number of Events	Censored	Survival time in months				Survival rate	p-value	
				Mean		Median				
				Estimate $\pm$ standard error	95% confidence interval	Estimate $\pm$ standard error	95% confidence interval			
<b>Overall survival</b>										
No	35	21	14	40.0%	18.9 $\pm$ 0.8	17.4–20.4	18.0 $\pm$ 0.5	17.0–19.0	11.0%	0.049
Yes	25	9	16	64.0%	21.1 $\pm$ 1.0	19.1–23.1	23.0 $\pm$ 2.8	17.5–28.5	0.0%	
Total	60	30	30	50.0%	19.8 $\pm$ 0.6	18.6–21.0	18.0 $\pm$ 1.5	15.0–21.0	41.0%	
<b>Relapse-free survival</b>										
No	27	15	12	44.4%	18.3 $\pm$ 1.0	16.2–20.3	17.0 $\pm$ 1.0	15.0–19.0	30.5%	0.036
Yes	20	5	15	75.0%	18.8 $\pm$ 0.4	17.9–19.6	Not reached		57.3%	
Total	47	20	27	57.4%	19.6 $\pm$ 0.8	18.0–21.2	18.0 $\pm$ 0.6	16.8–19.2	8.8%	

**Table 5** Univariate and multivariate Cox regression analyses of the rate of relapse-free survival

Covariate	Relapse-free survival			
	Univariate		Multivariate	
	p-value	Hazard ratio (95% confidence interval)	p-value	Hazard ratio (95% confidence interval)
Age (years)	0.87	1.00 (0.95–1.04)		
Gender	0.033	1.63 (1.04–2.56)	0.034	1.62 (1.04–2.52)
Histopathological subtype	0.339	0.49 (0.11–2.12)		
<b>Site of the primary tumor</b>				
Ascending colon	0.824	0.86 (0.23–3.25)		
Rectosigmoid	0.948	1.05 (0.25–4.39)		
Descending colon	0.087	3.79 (0.82–17.40)		
<b>Duke stage</b>				
A	0.375	1.89 (0.46–7.70)		
B	0.667	0.75 (0.20–2.83)		
C	0.16	0.41 (0.12–1.42)		
SPM and MPR	0.04	2.72 (1.05–7.10)		
Size of the largest PALN (mm)	0.043	0.83 (0.68–0.99)	0.145	0.86 (0.70–1.05)
<b>Type of primary operation</b>				
Right hemicolectomy	0.653	1.43 (0.30–6.72)		
Left hemi-colectomy	0.08	4.11 (0.85–20.00)		
Anterior resection	0.081	4.94 (0.82–29.71)		
PALND	0.062	0.38 (0.14–1.05)		
Preoperative chemoradiotherapy	< 0.001	7.32 (2.43–21.99)	0.001	6.16 (2.02–18.78)
Postoperative chemoradiotherapy	0.108	32.28 (0.46–2240.74)		

Abbreviations: MPR, metachronous para-aortic lymph node recurrence; PALN, para-aortic lymph node; PALND, para-aortic lymph node dissection; SPM, synchronous para-aortic lymph node metastasis.

**Table 6** Univariate and multivariate Cox regression analyses of the overall survival rate

Covariate	Overall survival			
	Univariate		Multivariate	
	p-value	Hazard ratio (95% confidence interval)	p-value	Hazard ratio (95% confidence interval)
Age (years)	0.199	1.03 (0.99–1.07)		
Gender	0.792	0.88 (0.35–2.23)		
Histopathological subtype	0.978	1.01 (0.41–2.52)		
Site of the primary tumor				
Ascending colon	0.458	1.52 (0.50–4.63)		
Recto-sigmoid	0.896	1.09 (0.31–3.87)		
Descending colon	0.076	3.39 (0.88–13.03)		
Duke stage				
A	0.998	1.00 (0.30–3.32)	0.959	1.04 (0.25–4.32)
B	0.173	0.47 (0.16–1.39)	0.961	1.04 (0.23–4.66)
C	0.031	0.35 (0.13–0.91)	0.229	0.52 (0.18–1.51)
SPM and MPR	0.029	2.61 (1.10–6.17)	0.079	2.48 (0.90–6.82)
Size of the largest PALN (mm)	0.211	0.91 (0.79–1.05)		
Type of primary operation				
Right hemicolectomy	0.506	1.45 (0.48–4.38)		
Left hemicolectomy	0.264	1.99 (0.59–6.67)		
Anterior resection	0.631	1.52 (0.27–8.44)		
PALND	0.204	1.66 (0.76–3.63)		
Preoperative chemoradiotherapy	0.002	0.21 (0.08–0.57)	0.003	0.01 (0.00–0.23)
Postoperative chemoradiotherapy	0.037	4.65 (1.10–19.62)	0.205	2.72 (0.58–12.76)
Relapse	0.011	3.37 (1.32–8.63)	0.004	0.01 (0.001–0.26)
Response to treatment	< 0.001	0.54 (0.39–0.75)	0.023	0.59 (0.38–0.93)

Abbreviations: MPR, metachronous para-aortic lymph node recurrence; PALN, para-aortic lymph node; PALND, para-aortic lymph node dissection; SPM, synchronous para-aortic lymph node metastasis.

and bone was higher among patients who did not undergo surgical excision.

Additionally, in patients who do not undergo PALND, metastasis to distant organs may result from unresected PALN metastasis.<sup>9</sup>

In the present study, the stage of the primary tumor was the most important prognostic factor for patient survival, and it was similar in patients who did and did not undergo resection.

## Conclusions

We showed that PALND in cases of CRC patients with SPM and MPR previously submitted to R0 resection was associated with favorable outcomes and better patient survival.

The accurate histopathological diagnosis of SPM and PMR can alter treatment strategies.

## Strengths of the Present Study

In the present report, we have overcome certain weaknesses of previous studies:<sup>1,12</sup> first, the present was a prospective

study, which enabled better data collection and analysis to reach accurate results; second, we included patients with SPM and MPR to verify the role of PALND whether it was done during resection of the primary tumor or resection of isolated PALN recurrence; third, we compared patients who underwent PALND and those who only underwent CRT; and, fourth, the present study was performed by a multidisciplinary team composed of gastrointestinal oncologists, oncologic surgeons, and radiologists, which made the management strategies more accurate.

## Limitations of the Study

Among the limitations of the present study, we can mention the fact that it was performed in a single center, the relatively small sample, and the relatively short follow-up.

## Recommendations

Larger prospective studies comparing patients submitted to different management strategies and with a longer follow-up are needed to determine the best treatment.

**Conflict of Interest**

The authors have no conflict of interests to declare.

**References**

- 1 Kim YI, Park IJ, Park JH, et al. Management of isolated para-aortic lymph node recurrence after surgery for colorectal cancer. *Ann Surg Treat Res* 2020;98(03):130–138
- 2 Patriarca S, Ferretti S, Zanetti R. TNM Classification of malignant tumours Eighth edition: which news? *Epidemiol Prev* 2017;41(02):140–3
- 3 Hashiguchi Y, Muro K, Saito Y, et al; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. *Int J Clin Oncol* 2020;25(01):1–42
- 4 Bellier J, De Wolf J, Hebbar M, et al. Repeated resections of hepatic and pulmonary metastases from colorectal cancer provide long-term survival. *World J Surg* 2018;42(04):1171–1179
- 5 Takeshima K, Yamafuji K, Asami A, et al. Successful resection of isolated paraaortic lymph node recurrence from advanced sigmoid colon cancer following 156 courses of FOLFIRI regimen. *Case Rep Surg* 2016;2016:4548798
- 6 Yeo SG, Kim DY, Kim TH, et al. Curative chemoradiotherapy for isolated retroperitoneal lymph node recurrence of colorectal cancer. *Radiother Oncol* 2010;97(02):307–311
- 7 Bae SU, Han YD, Cho MS, et al. Oncologic outcomes of colon cancer patients with extraregional lymph node metastasis: comparison of isolated paraaortic lymph node metastasis with resectable liver metastasis. *Ann Surg Oncol* 2016;23(05):1562–1568
- 8 Min BS, Kim NK, Sohn SK, Cho CH, Lee KY, Baik SH. Isolated paraaortic lymph-node recurrence after the curative resection of colorectal carcinoma. *J Surg Oncol* 2008;97(02):136–140
- 9 Ushigome H, Yasui M, Ohue M, et al. The treatment strategy of R0 resection in colorectal cancer with synchronous para-aortic lymph node metastasis. *World J Surg Oncol* 2020;18(01):229
- 10 Sahara K, Watanabe J, Ishibe A, et al. Long-term outcome and prognostic factors for patients with para-aortic lymph node dissection in left-sided colorectal cancer. *Int J Colorectal Dis* 2019;34(06):1121–1129
- 11 Nakai N, Yamaguchi T, Kinugasa Y, et al. Long-term outcomes after resection of para-aortic lymph node metastasis from left-sided colon and rectal cancer. *Int J Colorectal Dis* 2017;32(07):999–1007
- 12 Yamada K, Tsukamoto S, Ochiai H, Shida D, Kanemitsu Y. Improving selection for resection of synchronous para-aortic lymph node metastases in colorectal cancer. *Dig Surg* 2019;36(05):369–375
- 13 Selman TJ, Mann C, Zamora J, Appleyard TL, Khan K. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis. *CMAJ* 2008;178(07):855–862
- 14 Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. *Radiology* 2004;232(03):773–783
- 15 Kennedy ED, Milot L, Fruitman M, et al. Development and implementation of a synoptic MRI report for preoperative staging of rectal cancer on a population-based level. *Dis Colon Rectum* 2014; 57(06):700–708
- 16 Sasaki K, Nozawa H, Kawai K, et al. Management of isolated para-aortic lymph node recurrence of colorectal cancer. *Surg Today* 2019